SHP Antibody (A-7): sc-271470

SHP Antibody (A-7) is a mouse monoclonal IgG1 antibody that detects SHP in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). SHP, or short heterodimer partner, is an orphan nuclear receptor that plays a crucial role in regulating metabolic processes by modulating the activity of other nuclear receptors. SHP is primarily expressed in the liver, as well as in other tissues such as the fetal liver, adrenal gland, spleen, and small intestine, highlighting SHP′s importance in metabolic regulation and homeostasis. SHP′s unique structure, which includes dimerization and ligand-binding domains but lacks a conserved DNA binding domain, allows SHP to function as a negative regulator of various nuclear receptors, including thyroid receptors and estrogen receptors. This structural characteristic enables SHP to inhibit transcriptional activity through multiple mechanisms, such as dimerization that prevents DNA binding and competition with coactivators. SHP′s interaction with nuclear receptors is essential for maintaining cellular balance, particularly in bile acid regulation, where SHP acts as a protective factor against bile acid-mediated damage in cholestatic conditions. Anti-SHP antibody (A-7) is an invaluable tool for researchers studying SHP′s intricate roles in metabolic pathways and implications in various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SHP Antibody (A-7) References:

1. Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP).  |  Lam, IP., et al. 2009. Am J Physiol Gastrointest Liver Physiol. 297: G90-7. PMID: 19372104
2. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation.  |  Miao, J., et al. 2009. Genes Dev. 23: 986-96. PMID: 19390091
3. SHP-1 in cell-cycle regulation.  |  López-Ruiz, P., et al. 2011. Anticancer Agents Med Chem. 11: 89-98. PMID: 21291405
4. Metformin ameliorates IL-6-induced hepatic insulin resistance via induction of orphan nuclear receptor small heterodimer partner (SHP) in mouse models.  |  Kim, YD., et al. 2012. Diabetologia. 55: 1482-94. PMID: 22349108
5. Effects of Fenofibrate on the Expression of Small Heterodimer Partner (SHP) and Cytochrome P450 (CYP) 2D6.  |  Kent, R. and Jeong, H. 2017. Drug Metab Lett. 11: 68-72. PMID: 28403802
6. Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver.  |  Mathur, B., et al. 2021. Sci Adv. 7: PMID: 33883138
7. Small heterodimer partner (SHP) aggravates ER stress in Parkinson's disease-linked LRRK2 mutant astrocyte by regulating XBP1 SUMOylation.  |  Lee, JH., et al. 2021. J Biomed Sci. 28: 51. PMID: 34229656
8. Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP.  |  Hao, F., et al. 2021. Front Cell Dev Biol. 9: 730400. PMID: 34490276
9. Feeding activates FGF15-SHP-TFEB-mediated lipophagy in the gut.  |  Seok, S., et al. 2022. EMBO J. 41: e109997. PMID: 35686465
10. Targeting pathogenic macrophages by the application of SHP-1 agonists reduces inflammation and alleviates pulmonary fibrosis.  |  Hong, SY., et al. 2023. Cell Death Dis. 14: 352. PMID: 37291088

The preferred SHP antibody is SHP Antibody (H-5): sc-271511.